The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
Abstract
OBJECTIVES: Patients with RA have an increased prevalence of cardiovascular disease (CVD). This is due to traditional risk factors and the effects of chronic inflammation. MTX is the first-choice DMARD in RA. We performed a systematic literature review to determine whether MTX affects the risk of CVD in patients with RA. METHODS: We searched Medline, Embase, Cochrane database, database of abstracts of reviews of effects, health technology assessment and Science Citation Index from 1980 to 2008. Conference proceedings (British Society of Rheumatology, ACR and EULAR) were searched from 2005 to 2008. Papers were included if they assessed the relationship between MTX use and CVD in patients with RA. Two reviewers independently assessed each title and abstract for relevance and quality. RESULTS: A total of 2420 abstracts were identified, of which 18 fulfilled the inclusion criteria. Two studies assessed the relationship between MTX use and CVD mortality, one demonstrated a significant reduction in CVD mortality and the second a trend towards reduction. Five studies considered all-cause CVD morbidity. Four demonstrated a significant reduction in CVD morbidity and the fifth a trend towards reduction. MTX use in the year prior to the development of RA decreased the risk of CVD for 3-4 years. Four studies considered myocardial infarction, one demonstrated a decreased risk and three a trend towards decreased risk with MTX use. CONCLUSION: The current evidence suggests that MTX use is associated with a reduced risk of CVD events in patients with RA. This suggests that reducing the inflammation in RA using MTX not only improves disease-specific outcomes but may also reduce collateral damage such as atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Non-randomized observational studies report reductions in rates of vascular events and cardiovascular death among both rheumatoid arthritis and psoriasis patients being treated with weekly methotrexate in doses ranging from 10 to 20 mg.187,188”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Sanderson, S., Tatt, I. D., & Higgins, J. P. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym018 · Cited by 1,531
Being big or growing fast: systematic review of size and growth in infancy and later obesity
Baird, J., Fisher, D., Lucas, P., Kleijnen, J., Roberts, H., & Law, C. (2005) · BMJ · doi:10.1136/bmj.38586.411273.e0 · Cited by 1,185
Self-citationMethotrexate and mortality in patients with rheumatoid arthritis: a prospective study
Choi, H. K., Hernán, M. Á., Seeger, J. D., Robins, J. M., & Wolfe, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08213-2 · Cited by 1,133
Cardiovascular Risk and Inhibition of Cyclooxygenase
McGettigan, P., & Henry, D. A. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,106
Cardiovascular death in rheumatoid arthritis: A population‐based study
Kremers, H. M., Nicola, P., Crowson, C. S., Ballman, K. V., & Gabriel, S. E. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20878 · Cited by 941
Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis
Sattar, N. A., McCarey, D. W., Capell, H. A., & McInnes, I. B. (2003) · Circulation · doi:10.1161/01.cir.0000099844.31524.05 · Cited by 932
Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
Weinblatt, M. E., Coblyn, J. S., Fox, D. A., Fraser, P. A., Holdsworth, D. E., Glass, D. N., & Trentham, D. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121303 · Cited by 872
Ridker, P. M., Wilson, P. W. F., & Grundy, S. M. (2004) · Circulation · doi:10.1161/01.cir.0000132467.45278.59 · Cited by 645
Research works printed but not linked: 11
- Symmons, 1998, The Journal of Rheumatology, 25, 1072
- 1985, CLINICAL AND IMMUNOLOGIC EFFECTS IN A RANDOMIZED DOUBLEBLIND STUDY ANN INTERN MED, 103, 489
- 1985, A CONTROLLED CLINICAL TRIAL ARTHRITIS RHEUM, 28, 721
- Thompson, 1984, The Journal of Rheumatology, 11, 760
- 2008, Rheumatology, 47, ii49
- 2006, Annals of the Rheumatic Diseases, 65, 307
- 2008, Arthritis and rheumatism, 56, 688
- 2007, Arthritis and rheumatism, 56, S293
- GOODSON, 2008, The Journal of Rheumatology, 35, 945
- Seriolo, 2008, Clinical and experimental rheumatology, 26, 159
- Morgan, 1998, The Journal of Rheumatology, 25, 441
Cited by
Sorted by citations
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,862
Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M. H., Burmester, G. R., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J. L., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,764
Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V. P., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compán, M. V., Oliver, S. M., Schoels, M., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207524 · Cited by 1,481
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,431
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206624 · Cited by 907
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.007 · Cited by 702
Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease
Micha, R., Imamura, F., von Ballmoos, M. C. W., Solomon, D. H., Hernán, M. Á., Ridker, P. M., & Mozaffarian, D. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.06.054 · Cited by 542
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 467
Mason, J. C., & Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu403 · Cited by 420
Papp, K. A., Griffiths, C. E. M., Gordon, K. B., Lebwohl, M., Szapary, P. O., Wasfi, Y. S., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12214 · Cited by 414
Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE
Symmons, D. P. M., & Gabriel, S. E. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.75 · Cited by 406
Anti-inflammatory therapies for atherosclerosis
Bäck, M., & Hansson, G. K. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.5 · Cited by 380
Barnabe, C. C. M., Martin, B., & Ghali, W. A. (2010) · Arthritis Care & Research · doi:10.1002/acr.20371 · Cited by 372
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
Kitas, G. D., & Gabriel, S. E. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142133 · Cited by 326
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 319
Choy, E., Ganeshalingam, K., Semb, A. G., Szekanecz, Z., & Nurmohamed, M. T. (2014) · Rheumatology · doi:10.1093/rheumatology/keu224 · Cited by 310
Self-citationAtherosclerosis in rheumatoid arthritis: is it all about inflammation?
Skeoch, S., & Bruce, I. N. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.40 · Cited by 293
Crowson, C. S., Matteson, E. L., Roger, V. L., Therneau, T. M., & Gabriel, S. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.044 · Cited by 268
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study
van den Hoek, J., Boshuizen, H. C., Roorda, L. D., Tijhuis, G. J., Nurmohamed, M. T., van den Bos, G. A. M., & Dekker, J. (2016) · Rheumatology International · doi:10.1007/s00296-016-3638-5 · Cited by 237
Nast, A., Smith, C. H., Spuls, P. I., VALLE, G. L. A., Bata‐Csörgõ, Z., Boonen, H., de Jong, E. M. G. J., García-Doval, I., Gisondi, P., Kaur‐Knudsen, D., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16926 · Cited by 232
Cardiorheumatology: cardiac involvement in systemic rheumatic disease
Prasad, M., Hermann, J., Gabriel, S. E., Weyand, C. M., Mulvagh, S. L., Mankad, R., Oh, J. K., Matteson, E. L., & Lerman, A. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.206 · Cited by 218
Westlake, S., Colebatch, A. N., Baird, J., Curzen, N. P., Kiely, P. D. W., Quinn, M. A., Choy, E., Östör, A. J. K., & Edwards, C. J. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq316 · Cited by 213
Self-citationArida, A., Protogerou, A. D., Kitas, G. D., & Sfikakis, P. P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071890 · Cited by 199
Parisi, R., Rutter, M. K., Lunt, M., Young, H. S., Symmons, D. P. M., Griffiths, C. E. M., & Ashcroft, D. M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.87 · Cited by 185
Ahlehoff, O., Skov, L., Gislason, G., Lindhardsen, J., Kristensen, S. L., Iversen, L., Lasthein, S., Gniadecki, R., Dam, T. N., Torp-Pedersen, C. T., et al. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02593.x · Cited by 179
Liao, K. P., & Solomon, D. H. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes243 · Cited by 176
Zöller, B., Li, X., Sundquist, J., & Sundquist, K. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-41 · Cited by 172
Hugh, J. M., Voorhees, A. S. V., Nijhawan, R. I., Bagel, J., Lebwohl, M., Blauvelt, A., Hsu, S., & Weinberg, J. M. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.09.020 · Cited by 157
Zöller, B., Li, X., Sundquist, J., & Sundquist, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033442 · Cited by 154
The epidemiology of established rheumatoid arthritis
Otón, T., & Carmona, L. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101477 · Cited by 151
Charles‐Schoeman, C., Wicker, P. A., González-Gay, M. Á., Boy, M. G., Zuckerman, A. L., Soma, K., Geier, J. L., Kwok, K. K., & Riese, R. J. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.05.014 · Cited by 139
Co-morbidities in established rheumatoid arthritis
Gullick, N., & Scott, D. L. (2011) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2011.10.009 · Cited by 136
Novel anti-inflammatory therapies for the treatment of atherosclerosis
Khan, R., Spagnoli, V., Tardif, J., & L’Allier, P. L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.783 · Cited by 130
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J. N., Lynde, C. W., Pope, J. E., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141112 · Cited by 127
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
Lee, J. L., Sinnathurai, P., Buchbinder, R., Hill, C. L., Lassere, M. N., & MARCH, L. M. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1669-x · Cited by 123
Moreira, D. M., da Silva, R. L., Vieira, J. L., Fattah, T., Lueneberg, M. E., & Gottschall, C. A. M. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0094-z · Cited by 117
The Influence of Rheumatoid Arthritis Disease Characteristics on Heart Failure
Myasoedova, E., Crowson, C. S., Nicola, P., Kremers, H. M., Davis, J. M., Roger, V. L., Therneau, T. M., & Gabriel, S. E. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.100979 · Cited by 116
Propensity‐adjusted association of methotrexate with overall survival in rheumatoid arthritis
Wasko, M. C., Dasgupta, A., Hubert, H. B., Fries, J. F., & Ward, M. M. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37723 · Cited by 114
Cardiovascular effects of approved drugs for rheumatoid arthritis
Atzeni, F., Rodríguez‐Carrio, J., Popa, C. D., Nurmohamed, M. T., Szűcs, G., & Szekanecz, Z. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00593-3 · Cited by 108
Statins and inflammation: an update
Quist‐Paulsen, P. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283398e53 · Cited by 111
Risk factors for cardiovascular disease in rheumatoid arthritis
Gabriel, S. E., & Crowson, C. S. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834ff2fd · Cited by 102
Comorbidity in inflammatory bowel disease
López–Sanromán, A. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i22.2723 · Cited by 102
Yamamoto, K., Goto, H., Hirao, K., Nakajima, A., Origasa, H., Tanaka, K., Tomobe, M., & Totsuka, K. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141210 · Cited by 91
Özen, G., Pedro, S., & Michaud, K. D. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.200265 · Cited by 96
Treatment With Methotrexate Inhibits Atherogenesis in Cholesterol-Fed Rabbits
Bulgarelli, A., Dias, A. A. M., Caramelli, B., & Maranhão, R. C. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318241c385 · Cited by 95
Mikuls, T. R., Fay, B. T., Michaud, K. D., Sayles, H. R., Thiele, G. M., Caplan, L., Johnson, D. S., Richards, J. S., Kerr, G. S., Cannon, G. W., et al. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq232 · Cited by 95
Inflammation, Immune Activation, and CVD Risk in Individuals With HIV Infection
Stein, J. H., & Hsue, P. Y. (2012) · JAMA · doi:10.1001/jama.2012.8488 · Cited by 94
How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?
Kerola, A. M., Kauppi, M. J., Kerola, T. V., & Nieminen, T. V. M. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201334 · Cited by 88
Update on the NCEP ATP-III emerging cardiometabolic risk factors
Eckel, R. H., & Cornier, M. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-115 · Cited by 96
Atzeni, F., Turiel, M., Caporali, R. F., Cavagna, L., TOMASONI, L., Sitia, S., & Sarzi‐Puttini, P. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.07.018 · Cited by 87
Marks, J. L., & Edwards, C. J. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11436239 · Cited by 83
Self-citationAtherosclerosis and Rheumatoid Arthritis: More Than a Simple Association
Cavagna, L., Boffini, N., Cagnotto, G., Inverardi, F., Grosso, V., & Caporali, R. F. (2012) · Mediators of Inflammation · doi:10.1155/2012/147354 · Cited by 81
Atherosclerosis and Coronary Artery Disease
Zaromitidou, M., Siasos, G., Παπαγεωργίου, Ν., Oikonomou, E. K., & Tousoulis, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803312-8.00002-1 · Cited by 82
Tandon, R., Chew, G. M., Byron, M. M., Borrow, P., Niki, T., Hirashima, M., Barbour, J. D., Norris, P. J., Lanteri, M. C., Martin, J. N., et al. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0004 · Cited by 77
Managing the drug treatment of rheumatoid arthritis
Wilsdon, T. D., & Hill, C. L. (2017) · Australian Prescriber · doi:10.18773/austprescr.2017.012 · Cited by 77
Martínez, M. A. M., González‐Juanatey, C., Castañeda, S., Llorca, J., Ferraz‐Amaro, I., Fernández‐Gutiérrez, B., Díaz‐González, F., & González-Gay, M. Á. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.01.002 · Cited by 76
Bili, A., Tang, X., Pranesh, S., Bozaite, R., Morris, S. J., Antohe, J. L., Kirchner, H. L., & Wasko, M. C. M. (2014) · Arthritis Care & Research · doi:10.1002/acr.22166 · Cited by 75
Charles‐Schoeman, C., DeMasi, R., Valdez, H., Soma, K., Hwang, L., Boy, M. G., Biswas, P., & McInnes, I. B. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40911 · Cited by 75
Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
Judge, A., Garriga, C., Arden, N., Lovestone, S., Prieto‐Alhambra, D., Cooper, C. C., & Edwards, C. J. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.002 · Cited by 77
Self-citationLauper, K., Courvoisier, D. S., Chevallier-Ruggeri, P., Finckh, A., & Gabay, C. (2018) · Arthritis Care & Research · doi:10.1002/acr.23567 · Cited by 75
Cardiovascular Comorbidity in Rheumatic Diseases
Wright, K., Crowson, C. S., & Gabriel, S. E. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.10.003 · Cited by 73
Misra, D. P., & Shenoy, S. (2016) · Rheumatology International · doi:10.1007/s00296-016-3435-1 · Cited by 69
Ajeganova, S., Fairé, U. D., Jogestrand, T., Frostegård, J., & Hafström, I. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.111334 · Cited by 67
Deyab, G., Hokstad, I., Whist, J. E., Småstuen, M. C., Agewall, S., Lyberg, T., Ronda, N., Mikkelsen, K., Hjeltnes, G., & Hollan, I. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1439-1 · Cited by 67
New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis
Mahmoudi, M., Aslani, S., Fadaei, R., & Jamshidi, A. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12999 · Cited by 67
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker, P. M. (2013) · Europe PMC (PubMed Central) · Cited by 64
Rollefstad, S., Ikdahl, E., Hisdal, J., Olsen, I. C., Holme, I., Hammer, H. B., Smerud, K. T., Kitas, G. D., Pedersen, T. R., Kvien, T. K., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39114 · Cited by 67
Inflammation modulation and cardiovascular disease prevention
Awan, Z. A., & Genest, J. J. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314529350 · Cited by 65
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.05.010 · Cited by 66
Armstrong, A. W., Paul, C. F., Puig, L., Boehncke, W., Freeman, M., Torii, H., Papp, K. A., Griffiths, C. E. M., Blauvelt, A., Reich, K., et al. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-00340-3 · Cited by 65
Cardiovascular and Metabolic Protection by Vitamin E: A Matter of Treatment Strategy?
Ziegler, M., Wallert, M., Lorkowski, S., & Peter, K. (2020) · Antioxidants · doi:10.3390/antiox9100935 · Cited by 66
Cardiovascular Risk in Rheumatoid Arthritis
Gkaliagkousi, Ε., Gavriilaki, E., Doumas, M. N., Petidis, K., Aslanidis, S., & Δούμα, Σ. (2012) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31827846b1 · Cited by 63
Inflammatory Diseases and Vitamin E—What Do We Know and Where Do We Go?
Wallert, M., Börmel, L., & Lorkowski, S. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000097 · Cited by 68
Combating Inflammation in Cardiovascular Disease
Sethwala, A., Goh, I. Y., & Amerena, J. V. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.003 · Cited by 68
Methotrexate in Atherogenesis and Cholesterol Metabolism
Coomes, E., Chan, E. S. L., & Reiss, A. B. (2011) · Cholesterol · doi:10.1155/2011/503028 · Cited by 61
Systemic methotrexate for the treatment of psoriasis
Yélamos, O., & Puig, L. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1026894 · Cited by 61
Cardiovascular risk in rheumatoid arthritis: How to lower the risk?
der Stoep, D. F. V. B.-V., Klop, B., van Zeben, D., Hazes, J. M. W., & Cabezas, M. C. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.006 · Cited by 60
Inflammation in atherosclerotic cardiovascular disease
Shah, P. K., & Lecis, D. (2019) · F1000Research · doi:10.12688/f1000research.18901.1 · Cited by 58
Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?
Mason, A., Holmes, C., & Edwards, C. J. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.04.001 · Cited by 59
Self-citationSemb, A. G., Rollefstad, S., van Riel, P. L. C. M., Kitas, G. D., Matteson, E. L., & Gabriel, S. E. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204792 · Cited by 57
Mantel, Ä., Holmqvist, M. E., Nyberg, F., Tornling, G., Frisell, T., Alfredsson, L. S., & Askling, J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39267 · Cited by 57
Rheumatoid arthritis and cardiovascular disease
Barbhaiya, M., & Solomon, D. H. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835fd7f8 · Cited by 56
Tam, L., Li, E. K., Shang, Q., Tomlinson, B., Li, M., Leung, Y.-Y., Kuan, W.-P., Kwok, L., Li, T. K., Zhu, Y., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.131359 · Cited by 56
Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis
O'Neill, F., Charakida, M., Topham, E., McLoughlin, E., Patel, N. P., Sutill, E., Kay, C. W. M., D’Aiuto, F., Landmesser, U., Taylor, P. C., et al. (2016) · Heart · doi:10.1136/heartjnl-2015-308953 · Cited by 55
Atherosclerosis in psoriatic disease: latest evidence and clinical implications
Eder, L., & Gladman, D. D. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15591801 · Cited by 54
Cardiovascular safety of biologic therapies for the treatment of RA
Greenberg, J., Furer, V., & Farkouh, M. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.168 · Cited by 53
King, A., Schmaier, A., Harth, K. C., Kumins, N., Wong, V. L., Zidar, D. A., Kashyap, V., & Cho, J.-S. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.10.058 · Cited by 43
Immune-mediated mechanisms of atherosclerosis and implications for the clinic
Nus, M., & Mallat, Z. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1195686 · Cited by 57
Cardiovascular disease risk in rheumatoid arthritis: Progress, debate, and opportunity
Kramer, H. R., & Giles, J. T. (2010) · Arthritis Care & Research · doi:10.1002/acr.20386 · Cited by 53
A critical view on cardiovascular risk in systemic sclerosis
Psarras, A., Σουλαϊδόπουλος, Σ., Garyfallos, A., Kitas, G. D., & Dimitroulas, T. (2016) · Rheumatology International · doi:10.1007/s00296-016-3530-3 · Cited by 52
An, J., Nyarko, E., & Hamad, M. A. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04613-2 · Cited by 52
Effect of Anti-Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis
Yang, B., Ma, D., Xingxing, Z., Zhu, X., Yajing, W., Xu, K., & Liyun, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.812631 · Cited by 51
Nurmohamed, M. T., Bao, Y., Signorovitch, J., Trahey, A., Mulani, P. M., & Furst, D. E. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000080 · Cited by 51
López-Pedrera, C., Aguirre, M. A., Barbarroja, N., & Cuadrado, M. J. (2010) · BioMed Research International · doi:10.1155/2010/607084 · Cited by 50
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 52
Houge, I. S., Hoff, M., Thomas, R., & Videm, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-60621-2 · Cited by 52
Metadata
- Authors
- Westlake, S. L., Colebatch, A. N., Baird, J., Kiely, P., Quinn, M., Choy, E., Ostor, A. J. K., & Edwards, C. J.
- Affiliations
- King's College London (GB)
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-27
- Volume
- 49
- Issue
- 2
- Pages
- 295-307
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2100260684
- Cited by
- 357
- References
- 57
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 7 · 2023: 10 · 2022: 15 · 2021: 18 · 2020: 15 · 2019: 26 · 2018: 20 · 2017: 25 · 2016: 32 · 2015: 38 · 2014: 25 · 2013: 33 · 2012: 42
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lara D. Veeken (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Keywords
- methotrexate, rheumatoid arthritis, cardiovascular disease, cardiovascular mortality, cardiovascular morbidity, myocardial infarction, atherosclerosis, disease-modifying antirheumatic drugs, chronic inflammation
- MeSH terms
- Arthritis, Rheumatoid, Cardiovascular Diseases, Humans, Immunosuppressive Agents, Insulin Resistance, Lipids, Methotrexate, Antirheumatic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
